{
    "root": "30144cfc-0fb1-8d62-e063-6394a90acba4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin and Clavulanate Potassium",
    "value": "20250311",
    "ingredients": [
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2877"
        },
        {
            "name": "HYPROMELLOSE 2910 (50 MPA.S)",
            "code": "1IVH67816N",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "ORANGE",
            "code": "5EVU04N5QU",
            "drugbank_id": "https://go.drugbank.com/drugs/DB10549"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SUCCINIC ACID",
            "code": "AB6MNQ6J6L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15741"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        },
        {
            "name": "CLAVULANATE POTASSIUM",
            "code": "Q42OMW3AT8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_487869"
        }
    ],
    "indications": {
        "text": "amoxicillin clavulanate potassium oral suspension indicated treatment infections adults pediatric patients , due susceptible isolates designated bacteria conditions listed : lower respiratory tract infections\u2013 caused beta-lactamase\u2013producing isolates haemophilus influenzaeand moraxella catarrhalis . acute bacterial otitis media\u2013 caused beta-lactamase\u2013producing isolates h. influenzaeand m. catarrhalis . sinusitis\u2013 caused beta-lactamase\u2013producing isolates h. influenzaeand m. catarrhalis . skin skin structure infections\u2013 caused beta-lactamase\u2013producing isolates staphylococcus aureus , escherichia coli , klebsiellaspecies . urinary tract infections\u2013 caused beta-lactamase\u2013producing isolates e. coli , klebsiellaspecies , enterobacterspecies . limitations susceptibility test results show susceptibility amoxicillin , indicating beta-lactamase production , amoxicillin clavulanate potassium oral suspension used . usage reduce development drug-resistant bacteria maintain effectiveness amoxicillin clavulanate potassium oral suspension antibacterial drugs , amoxicillin clavulanate potassium oral suspension used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "acute bacterial otitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_206994"
            }
        ]
    },
    "contraindications": {
        "text": "adults pediatric patients greater 40 kg : 500 875 mg every 12 hours 250 500 mg every 8 hours , based amoxicillin component . ( 2.2 , 2.3 ) pediatric patients aged 12 weeks ( 3 months ) older : 25 45 mg/kg/day every 12 hours 20 40 mg/kg/day every 8 hours , adult dose . ( 2.3 ) neonates infants less 12 weeks age : 30 mg/kg/day divided every 12 hours , based amoxicillin component . 125 mg/31.25 mg per 5 ml oral suspension recommended . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "amoxicillin clavulanate potassium oral suspension usp , 200 mg/28.5 mg per 5 mlis white off-white granular powder \u2013 5 ml reconstituted white pale yellow , orange flavored suspension contains 200 mg amoxicillin trihydrate 28.5 mg clavulanic acid potassium salt ( equivalent 34 mg clavulanate potassium ) . bottles 100 ml ndc 68071-3807-1 dispense original container . store dry powder at20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) . [ usp controlled room temperature . ] store reconstituted suspension refrigeration . discard unused suspension 10 days . keep reach children .",
    "adverseReactions": "history serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin clavulanate potassium oral suspension beta-lactams ( e.g . , penicillins cephalosporins ) . ( 4.1 ) history cholestatic jaundice/hepatic dysfunction associated amoxicillin clavulanate potassium oral suspension . ( 4.2 )",
    "indications_original": "Amoxicillin and clavulanate potassium for oral suspension is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below:\n                  \n                  \n                     \n                        Lower Respiratory Tract Infections\u2013 caused by beta-lactamase\u2013producing isolates of\n  \n   Haemophilus influenzaeand\n  \n   Moraxella catarrhalis.\n \n  \n                     \n                        Acute Bacterial Otitis Media\u2013 caused by beta-lactamase\u2013producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n \n  \n                     \n                        Sinusitis\u2013 caused by beta-lactamase\u2013producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n \n  \n                     \n                        Skin and Skin Structure Infections\u2013 caused by beta-lactamase\u2013producing isolates of\n  \n   Staphylococcus aureus,\n  \n   Escherichia coli, and\n  \n   Klebsiellaspecies.\n \n  \n                     \n                        Urinary Tract Infections\u2013 caused by beta-lactamase\u2013producing isolates of\n  \n   E. coli,\n  \n   Klebsiellaspecies, and\n  \n   Enterobacterspecies.\n \n  \n                  \n                  \n                     Limitations of Use\n                     \n                  \n                  When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, amoxicillin and clavulanate potassium for oral suspension should not be used.\n                  \n                  \n                     Usage\n                  \n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension\u00a0 and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension\u00a0 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "Adults and Pediatric Patients greater than 40 kg:\u00a0500 or 875 mg every 12 hours or\u00a0250 or 500 mg every 8 hours,\u00a0 based on amoxicillin component. \u00a0( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/31.25 mg per 5 mL oral suspension is recommended. ( 2.3 )",
    "warningsAndPrecautions_original": "Amoxicillin and Clavulanate Potassium for Oral Suspension USP, \n                     200 mg/28.5 mg per 5 mLis a white to off-white granular powder \u2013 Each 5 mL of reconstituted white to pale yellow, orange flavored suspension contains 200 mg of amoxicillin as the trihydrate and 28.5 mg of clavulanic acid as the potassium salt (equivalent to 34 mg of clavulanate potassium).\n  \n                     \n                Bottles of 100 mL                   NDC 68071-3807-1\n  \n                     \n                     \n                     \nDispense in original container.\n  \n                     \n                     Store dry powder\n                     at20\u00ba to 25\u00baC (68\u00ba to 77\u00baF). [See USP Controlled Room Temperature.]\n  \n                     \nStore reconstituted suspension under refrigeration. Discard unused suspension after 10 days.\n  \n                     \nKeep out of the reach of children.",
    "adverseReactions_original": "History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin and clavulanate potassium for oral suspension or to other beta-lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin and clavulanate potassium for oral suspension. ( 4.2 )",
    "drug": [
        {
            "name": "Amoxicillin and Clavulanate Potassium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2676"
        }
    ]
}